Sign up Australia
Proactive Investors - Run By Investors For Investors

Cynata Therapeutics and Japan's Regience K.K. in stem cell alliance

Cynata Therapeutics and Japan's Regience K.K. in stem cell alliance

Cynata Therapeutics (ASX:CYP) has signed an agreement with Regience K.K., a regenerative medicine venture company based in Japan for an investment in Cynata of A$250,000.

This is the first part of an alliance which would entail the companies co-operating to develop and commercialise Cynata’s therapeutic mesenchymal stem cell (MSC) technology for Japan and for certain Asian countries.

If Regience proceeds it must invest an additional A$2,250,000 in new ordinary shares issued by Cynata, based on the same pricing structure and escrow as the initial investment.

This additional investment would provide Regience with an exclusive two year option to Cynata’s Cymerus technology.

The Cymerus stem cell technology provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale.

The potential commercial market in Japan and neighbouring countries for the technology's therapeutic use in these markets could result in hundeds of millions of dollars the company said.

Regience K.K. develops multiple cell-based products and has seven regenerative medicine projects in a research & development pipeline.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

 

 

View full CYP profile View Profile

Cynata Therapeutics Ltd Timeline

Related Articles

Callitas CEO James Thompson
July 21 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
scientist with vial
September 25 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use